Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) have been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus target price of $19.67 for the company and are expecting that the company will post ($0.32) EPS for the current quarter, according to Zacks. Zacks has also given Oxford Immunotec Global PLC an industry rank of 93 out of 265 based on the ratings given to its competitors.
A number of research analysts have recently commented on OXFD shares. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Sunday, June 26th. Finally, Zacks Investment Research downgraded Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th.
Oxford Immunotec Global PLC (NASDAQ:OXFD) traded down 2.69% during midday trading on Thursday, reaching $11.93. 45,665 shares of the company’s stock traded hands. Oxford Immunotec Global PLC has a 52-week low of $7.73 and a 52-week high of $14.25. The stock has a 50-day moving average of $10.84 and a 200 day moving average of $9.86. The company’s market cap is $269.25 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The firm earned $19.20 million during the quarter, compared to analysts’ expectations of $18.10 million. Oxford Immunotec Global PLC had a negative net margin of 34.33% and a negative return on equity of 27.23%. The business’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.33) earnings per share. On average, analysts anticipate that Oxford Immunotec Global PLC will post ($1.29) earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in OXFD. Renaissance Technologies LLC increased its position in Oxford Immunotec Global PLC by 51.6% in the first quarter. Renaissance Technologies LLC now owns 81,700 shares of the company’s stock valued at $810,000 after buying an additional 27,800 shares in the last quarter. Geode Capital Management LLC increased its stake in Oxford Immunotec Global PLC by 32.2% in the first quarter. Geode Capital Management LLC now owns 33,614 shares of the company’s stock worth $333,000 after buying an additional 8,180 shares in the last quarter. State Street Corp increased its stake in Oxford Immunotec Global PLC by 4.1% in the first quarter. State Street Corp now owns 235,187 shares of the company’s stock worth $2,329,000 after buying an additional 9,245 shares in the last quarter. Societe Generale purchased a new stake in Oxford Immunotec Global PLC during the second quarter worth $114,000. Finally, SG Americas Securities LLC purchased a new stake in Oxford Immunotec Global PLC during the second quarter worth $114,000. 78.02% of the stock is owned by institutional investors.
Oxford Immunotec Global PLC Company Profile
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.